Clinical trials
Completed Pituitary Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2006 | 4 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Corcept Therapeutics | 3 |
| Ascendis Pharma Endocrinology Division A/S | 2 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2 |
| LG Life Sciences | 2 |
| Massachusetts General Hospital | 2 |
| Novartis Pharmaceuticals | 2 |
| US Department of Veterans Affairs | 2 |
| Washington University School of Medicine | 2 |
| Aalborg University Hospital | 1 |
| Ascendis Pharma A/S | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pituitary Diseases | 39 |
| Dwarfism, Pituitary | 9 |
| Pituitary Neoplasms | 8 |
| Pituitary ACTH Hypersecretion | 5 |
| Endocrine System Diseases | 4 |
| Failure to Thrive | 4 |
| Hypopituitarism | 4 |
| ACTH Syndrome, Ectopic | 3 |
| Cushing Syndrome | 3 |
| Adrenal Cortex Neoplasms | 2 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.